The Utility of Galectin-3 for Predicting Cause-Specific Death in Hospitalized Patients With Heart Failure

Zhang, Yuhui; Zhang, Rongcheng; An, Tao; Huang, Yan; Guo, Xinying; Yin, Shijie; Wang, Yunlong; Ji, Shiming; Lü, Rong; Zhang, Jiän; Maisel, Alan S.

doi:10.1016/j.cardfail.2014.10.006

Cited by 23 publications

(23 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The remaining 2 studies [6,9] which reported galectin-3 as categorical variable demonstrated a statistically significant 30% increase (HR 1.30, 95% CI 1.00-1.69) in all-cause mortality of HF patients with higher serum galectin-3 level (Fig. 1B).Three studies [8,12,13] evaluated the association between galectin-3 and CV mortality of HF, regarding galectin-3 as continuous variable. Pooling these 3 studies indicated that every 1% increase in galectin-3 was associated with a 59% increase in the risk of CV mortality (HR 1.59, 95% CI 1.04-2.42, I 2 = 75.1%) (Fig.…”

mentioning

confidence: 93%

“…8419 participants were enrolled in these studies, with the duration ranged from 1 to 8.7 years. Among them,7,8,[10][11][12][13]] considered galectin-3 as continuous variable, the pooled results of these 9 studies revealed that for every 1% increase in galectin-3, the risk of all-cause mortality increased by 28% (HR 1.28, 95% CI 1.10-1.48). Significant heterogeneity was found among these studies (I 2 = 82.1%) (Fig.…”

mentioning

confidence: 98%

“…Three studies [8,12,13] evaluated the association between galectin-3 and CV mortality of HF, regarding galectin-3 as continuous variable. Pooling these 3 studies indicated that every 1% increase in galectin-3 was associated with a 59% increase in the risk of CV mortality (HR 1.59, 95% CI 1.04-2.42, I 2 = 75.1%) (Fig.…”

mentioning

confidence: 99%

“…Eleven studies [3][4][5][6][7][8][9][10][11][12][13] investigated the relationship between galectin-3 and all-cause mortality. 8419 participants were enrolled in these studies, with the duration ranged from 1 to 8.7 years.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Prognostic value of serum galectin-3 in patients with heart failure: A meta-analysis

Chen

Hou

Zhang

et al. 2015

International Journal of Cardiology

View full text Add to dashboard Cite

mentioning

confidence: 93%

mentioning

confidence: 98%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Prognostic value of serum galectin-3 in patients with heart failure: A meta-analysis

Chen

Hou

Zhang

et al. 2015

International Journal of Cardiology

View full text Add to dashboard Cite

“…It is reported to be involved in cell adhesion, activation, growth and differentiation and also apoptosis (8). Overexpression of GAL-3 is associated with heart failure, including myofiboblast proliferation, fibrogenesis, tissue repair, inflammation and ventricular remodeling (9). Serum GAL-3 is a recent biomarker in HF with strong prognostic implications.…”

Section: Introductionmentioning

confidence: 99%

High GAL-3 may be Associated with Higher Age and Low Levels of Chloride, RDW, and MCHC in Heart Failure

Kaya¹,

Ademoğlu²,

Yiğit³

et al. 2016

Ulutas Med J

View full text Add to dashboard Cite

Background: Elevated galectin-3 (GAL-3) levels have been associated with decompansated heart failure (HF) which is a complex mechanical and neurohormonal syndrome. Many clinical and biochemical factors have been implicated in the pathopyhsiology of HF. In a group of patients who are referred to the emergency clinic for HF, GAL-3 levels and their association with various clinical and biochemical parameters were determined. GAL-3levels were measured with the VIDAS automated enzyme-linked fluorescent assay.Method: Our study group consists of 70 patients (33 women and 37 men) and 25 healthy controls. All 70 patients had at least Class II or higher levels of HF according to NYHA criteria.Results: GAL-3 was significantly higher in the patient group (17.98 vs.10.24 ng/ml; p<000,1). 53 patients had atherosclerotic heart disease, 14 patients had intracardiac cardioverter-defibrillator implantation (ICD), 37 atrial fibrillation and 25 patients had type 2 diabetes mellitus. Low levels of chlorine, low red cell width (RDW), as a low blood count parameter low mean corpuscular hemoglobin concentration (MCHC) and higher age were associated with elevated levels of GAL-3.Statistical analysis has shown that galectin-3 was significantly associated with hypochloremia (p=0.002), MCHC (p=0.002), RDW (p=0.009). Age, hyponatremia and anemia are clinically slightly relevant indices of decompansated HF associated with high levels of GAL-3. Conclusion:The measurement of GAL-3 may represent a new alternative biomarker in decision making for HF. Clinical parameters associated with GAL-3 may illuminate new pathopysiologic mechanisms in HF.

show abstract

Galectin‐3 levels and long‐term all‐cause mortality and hospitalization in heart failure patients: a meta‐analysis

Cheng,

Maciej,

Thiele

et al. 2024

ESC Heart Failure

View full text Add to dashboard Cite

AimsThis meta‐analysis investigated the dose–response relationship between circulating galectin‐3 levels and adverse outcomes in patients with heart failure (HF).Methods and resultsPubMed and Embase were screened for studies on galectin‐3 and HF. The outcomes of interest were all‐cause mortality (ACM), and all‐cause mortality or HF‐related rehospitalization (ACM/HFR), with a follow‐up time of more than 6 months. For categorical variables, comparisons between groups with the highest and lowest galectin‐3 levels were pooled. For continuous variables, the risks of ACM and ACM/HFR increase per 1‐standard deviation (SD) and 1‐unit after logarithmic transformation galectin‐3 levels were pooled. A random‐effects model was employed to calculate the pooled results, and all pooled results were expressed as hazard ratios (HRs) and 95% confidence intervals (CIs). Besides, a dose–response analysis was performed. Twenty‐four cohort studies were included. In HF patients, higher circulating galectin‐3 levels were significantly associated with a higher risk of long‐term ACM (HR, 1.65; 95% CI 1.28–2.13; I2 = 66%), and 1 ng/mL increase in galectin‐3 was associated with a 4% (HR, 1.04; 95% CI 1.02–1.06; P = 0.002) increase in hazard. Similarly, higher circulating galectin‐3 levels were significantly associated with a higher risk of long‐term ACM/HFR (HR, 1.52; 95% CI, 1.15 to 2.00; I2 = 76%), and 1 ng/mL increase in galectin‐3 was associated with a 3% (HR, 1.03; 95% CI 1.02–1.04; P < 0.001) increase in hazard. An increase of 1‐SD in galectin‐3 units was associated with a 29% increased hazard of long‐term ACM (HR 1.29; 95% CI 1.13–1.48; I2 = 42%) and a 22% increased hazard of ACM/HFR (HR 1.22; 95% CI 1.07–1.38; I2 = 60%). Similarly, an increase of 1‐log in galectin‐3 units was associated with a 98% higher hazard of long‐term ACM (HR 1.98; 95% CI 1.48–2.65; I2 = 41%) and an 83% higher hazard of ACM/HFR in HF patients (HR 1.83; 95% CI 1.02–3.28; I2 = 7%). Correlation analysis showed a moderate positive correlation between baseline galectin‐3 and N terminal pro brain natriuretic peptide levels (r = 0.48, P = 0.045) and a weak negative correlation with eGFR (r = −0.39, P = 0.077).ConclusionsHigher circulating galectin‐3 levels after hospitalization of HF patients are linearly and positively associated with the risk of long‐term ACM and ACM/HFR.

show abstract

The Utility of Galectin-3 for Predicting Cause-Specific Death in Hospitalized Patients With Heart Failure

Cited by 23 publications

References 26 publications

Prognostic value of serum galectin-3 in patients with heart failure: A meta-analysis

Prognostic value of serum galectin-3 in patients with heart failure: A meta-analysis

High GAL-3 may be Associated with Higher Age and Low Levels of Chloride, RDW, and MCHC in Heart Failure

Galectin‐3 levels and long‐term all‐cause mortality and hospitalization in heart failure patients: a meta‐analysis

Contact Info

Product

Resources

About